MCID: ACT135
MIFTS: 52

Acute Graft Versus Host Disease

Categories: Rare diseases, Blood diseases

Aliases & Classifications for Acute Graft Versus Host Disease

MalaCards integrated aliases for Acute Graft Versus Host Disease:

Name: Acute Graft Versus Host Disease 50 56
Acute Graft-Versus-Host Disease 52
Acute Gvh Disease 69
Acute Gvhd 50

Classifications:

Orphanet: 56  
Rare immunological diseases


External Ids:

Orphanet 56 ORPHA99920
UMLS via Orphanet 70 C0856825
ICD10 via Orphanet 34 T86.0

Summaries for Acute Graft Versus Host Disease

MalaCards based summary : Acute Graft Versus Host Disease, also known as acute graft-versus-host disease, is related to chronic graft versus host disease and lymphoma. An important gene associated with Acute Graft Versus Host Disease is ARHGAP45 (Rho GTPase Activating Protein 45), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Methotrexate and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and t cells, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and digestive/alimentary

Related Diseases for Acute Graft Versus Host Disease

Diseases in the Acute Graft Versus Host Disease family:

Chronic Graft Versus Host Disease

Diseases related to Acute Graft Versus Host Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 271)
id Related Disease Score Top Affiliating Genes
1 chronic graft versus host disease 30.6 IFNG IL10 IL2
2 lymphoma 29.8 IFNG IL10 IL2 IL4 TNF
3 pure autonomic failure 10.8 IL10 TNF
4 bulbospinal polio 10.7 IFNG IL2
5 scirrhous adenocarcinoma 10.7 IL2 TNF
6 multiple familial trichoepithelioma 10.7 IL10 TNF
7 dumping syndrome 10.7 IFNG IL10
8 sternal cleft 10.7 IFNG TNF
9 anthracosilicosis 10.7 IFNG IL2
10 myoclonic astatic epilepsy 10.7 IFNG IL4
11 type 1 papillary adenoma of the kidney 10.7 IL10 TNF
12 endosalpingiosis 10.7 IL10 TNF
13 mosaic trisomy 1 10.7 IFNG TNF
14 hematopoietic stem cell transplantation 10.7
15 primary systemic mycosis 10.7 IFNG TNF
16 spirillary rat-bite fever 10.7 IL2 TNF
17 diabetic angiopathy 10.7 IL10 IL4
18 visual snow syndrome 10.7 IL2 IL4
19 idiopathic dilatation of the pulmonary artery 10.6 IL10 TNF
20 hemangioma of orbit 10.6 IL2 TNF
21 deafness, autosomal recessive 22 10.6 IL10 IL4
22 tabatznik syndrome 10.6 IL18 TNF
23 autoimmune retinopathy 10.6 IL2RA TNF
24 ethmoid sinus adenocarcinoma 10.6 IL10 TNF
25 goat milk allergy 10.6 IFNG IL4
26 facial paralysis 10.6 IL10 IL18
27 congenital insensitivity to pain with hyperhidrosis 10.6 IL10 NOD2
28 tarsal tunnel syndrome 10.5 IL10 TNF
29 crustacean allergy 10.5 IL10 IL18
30 sezary's disease 10.5 IFNG IL10 IL2
31 hepadnavirus infection 10.5 IFNG IL10 TNF
32 senile reticular retinal degeneration 10.5 IFNG IL10 TNF
33 psychologic dyspareunia 10.5 IFNG IL10 TNF
34 conduct disorder 10.5 IFNG IL10 TNF
35 autoimmune polyglandular syndrome type 3 10.5 IFNG IL2 TNF
36 bartonellosis 10.5 IFNG IL10 TNF
37 x-linked dominant intellectual disability-epilepsy syndrome 10.5 IL18 IL2
38 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids 10.5 IFNG IL10 IL2RA
39 neuromuscular disease 10.5 NOD2 TNF
40 disease of mental health 10.5 IFNG IL10 TNF
41 urethral intrinsic sphincter deficiency 10.5 IL4 TNF
42 extrahepatic bile duct adenocarcinoma 10.5 IFNG IL10 TNF
43 cornea cancer 10.5 IFNG IL10 TNF
44 dentinogenesis imperfecta 10.5 IFNG IL10 TNF
45 thelaziasis 10.5 IFNG IL10 IL4
46 pmm2-congenital disorder of glycosylation 10.5 IL2 IL4
47 atypical lichen myxedematosus 10.5 IL2RA TNF
48 centronuclear myopathy 5 10.5 IFNG IL10 IL4
49 keratomalacia 10.5 IFNG IL10 TNF
50 louping ill 10.5 IFNG IL2 TNF

Graphical network of the top 20 diseases related to Acute Graft Versus Host Disease:



Diseases related to Acute Graft Versus Host Disease

Symptoms & Phenotypes for Acute Graft Versus Host Disease

GenomeRNAi Phenotypes related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.78 IL18 IL2 IL2RA NOD2 TNF GZMB
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.78 IL2 IL2RA NOD2 TNF GZMB IL10

MGI Mouse Phenotypes related to Acute Graft Versus Host Disease:

44 (show all 12)
id Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 10.19 IL4 NOD2 TNF TNFRSF4 FASLG IFNG
2 cellular MP:0005384 10.16 FASLG IFNG IL10 IL18 IL2 IL4
3 hematopoietic system MP:0005397 10.13 FASLG IFNG IL10 IL18 IL2 IL2RA
4 growth/size/body region MP:0005378 10.11 IFNG IL10 IL18 IL2 IL2RA IL4
5 homeostasis/metabolism MP:0005376 10.1 FASLG IFNG IL10 IL18 IL2 IL2RA
6 immune system MP:0005387 10.07 NOD2 TNF TNFRSF4 FASLG IFNG IL10
7 endocrine/exocrine gland MP:0005379 10.02 FASLG IFNG IL10 IL2 IL2RA IL4
8 integument MP:0010771 9.87 FASLG IFNG IL10 IL18 IL4 TNF
9 mortality/aging MP:0010768 9.85 FASLG IFNG IL10 IL18 IL2 IL2RA
10 liver/biliary system MP:0005370 9.8 FASLG IFNG IL10 IL2 IL4 TNF
11 respiratory system MP:0005388 9.56 FASLG IFNG IL10 IL2 IL2RA IL4
12 vision/eye MP:0005391 9.23 FASLG IFNG IL10 IL18 IL2 IL2RA

Drugs & Therapeutics for Acute Graft Versus Host Disease

Drugs for Acute Graft Versus Host Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 371)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 1959-05-2, 59-05-2 126941
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 22916-47-8 4189
3
Tacrolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 104987-11-3 445643 439492
4
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
5
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
6
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53123-88-9 5284616 6436030 46835353
7
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
8 Thiotepa Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 52-24-4 5453
9
Basiliximab Approved, Investigational Phase 4,Phase 3,Phase 2 152923-56-3, 179045-86-4
10
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 128794-94-5 5281078
11
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 24280-93-1 446541
12
Foscarnet Approved Phase 4,Phase 2 63585-09-1, 4428-95-9 3415
13
Ganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2 82410-32-0 3454
14
Busulfan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 55-98-1 2478
15
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 21679-14-1, 75607-67-9 30751
16
Vidarabine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 24356-66-9 32326 21704
17
Daclizumab Approved, Investigational Phase 4,Phase 3,Phase 2 152923-56-3
18
Infliximab Approved Phase 4,Phase 2,Phase 1 170277-31-3
19
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
20
Menthol Approved Phase 4,Phase 2,Phase 1 2216-51-5 16666
21
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147-94-4 6253
22
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
23
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
24
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 59-30-3 6037
25
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 58-05-9 143 6006
26
Cholecalciferol Approved, Nutraceutical Phase 4 67-97-0 6221 10883523 5280795
27
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
28
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
29
Phosphonoacetic Acid Experimental Phase 4,Phase 2 4408-78-0 546
30
Treosulfan Investigational Phase 4,Phase 3,Phase 2 299-75-2 9296
31
Lactitol Investigational Phase 4,Phase 2 585-86-4 3871
32 Antibodies Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
33 Antirheumatic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
34 Dermatologic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
35 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Immunoglobulins Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
37 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
38 Antifungal Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
39 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
40 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
41 Antimetabolites, Antineoplastic Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
42 Calcineurin Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
43 Cyclosporins Phase 4,Phase 2,Phase 3,Phase 1
44 Folic Acid Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
45 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
46 Vitamin B Complex Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
47 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 890)

id Name Status NCT ID Phase Drugs
1 Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD Completed NCT00574470 Phase 4 daclizumab, infliximab
2 Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule/Injection) and Methotrexate (MTX) Combination Therapy for Prevention of Graft Versus Host Disease (GVHD) in Patients Who Received Peripheral Hematopoietic Stem Cell Transplantation Fro Completed NCT02660684 Phase 4 Prograf;Methotrexate;Cyclosporine
3 Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Allo-HSCT Completed NCT01232504 Phase 4 rhGM-CSF group;rhG-CSF+rhGM-CSF group;rhG-CSF group
4 A Study Comparing the Withdrawal of Steroids or Tacrolimus in Kidney Transplant Recipients Completed NCT00195429 Phase 4 Tacrolimus;Sirolimus;prednisone
5 Study Comparing Cyclosporine Dose Reduction vs. Cyclosporine Elimination in Kidney Transplant Recipients Taking Sirolimus Completed NCT00195468 Phase 4 CYCLOSPORINE
6 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
7 Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major Recruiting NCT02342145 Phase 4 Basiliximab,;cyclosporine A;Methotrexate;Mycophenolate mofetil
8 Efficacy and Safety Study of ATG for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT Recruiting NCT02677181 Phase 4 ATG;CsA;mycophenolate mofetil;Methotrexate
9 Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT Recruiting NCT02634294 Phase 4 Peg interferon alfa-2b
10 Post-transplantation Cyclophosphamide for Haploidentical Transplant From Maternal or Collateral Donors Recruiting NCT02412423 Phase 4 post-transplantation cyclophosphamide
11 Anti-thymocyte Globulins for Graft-versus-host Disease Prophylaxis Recruiting NCT01856803 Phase 4 anti thymoglobulin
12 Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections Recruiting NCT02805946 Phase 4 posaconazole
13 Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients Recruiting NCT03150134 Phase 4 Cyclosporine;routine reduction of immunosuppressive drugs(cyclosporine)
14 CMV-CTL for the Treatment of CMV Infection After HSCT Recruiting NCT03004261 Phase 4 Foscarnet;Ganciclovir
15 ALL SCTped FORUM - Pharmacogenomic Study (add-on Study) Recruiting NCT02670564 Phase 4
16 Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major Recruiting NCT03171831 Phase 4 Busulfan;Cyclophosphamide;Fludarabine;Mycophenolate mofetil;Tacrolimus;Methotrexate;Thymoglobulin;Basiliximab
17 A Optimal Anti-Thymoglobuline (ATG) Dose Decrease cGVHD But Not Increase Leukemia Relapse for Haplo-HSCT Not yet recruiting NCT03190733 Phase 4 ATG
18 Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation Not yet recruiting NCT02784561 Phase 4 Busulfan (Zhejiang Otsuka Pharmaceutical Co. Ltd);Cytarabine(Actavis Italy S.p.A);Fludarabine (Bayer);granulocyte colony-stimulating factor (KirinKunpeng);rabbit ATG(Sanofi/Genzyme)
19 A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT Not yet recruiting NCT03176849 Phase 4
20 Extracorporeal Photopheresis for Acute Graft Versus Host Disease Unknown status NCT00179855 Phase 2, Phase 3
21 MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis Unknown status NCT02270307 Phase 2, Phase 3 Cyclophosphamide
22 Randomized Study of ATG for Graft Versus Host Disease (GVHD) Prevention in Paediatric Patients Given an Unrelated Donor Stem Cell Transplantation Unknown status NCT00934557 Phase 3 ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius
23 Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation Unknown status NCT00207792 Phase 3 filgrastim
24 The Effect of Folinic Acid Rescue Following MTX GVHD Prophylaxis on Regimen Related Toxicity and Transplantation Outcome Unknown status NCT02506231 Phase 2, Phase 3 Folinic acid;Placebo
25 Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia Unknown status NCT01423747 Phase 3 VP16;VP16, ATG;Fludarabine, OKT3, Treosulfan, Thiotepa;VP16, ATG
26 ALL-SCT BFM International- HSCT in Children and Adolescents With ALL Unknown status NCT01423500 Phase 3 VP16;VP16, ATG;Fludarabine, OKT3, Treosulfan, Thiotepa;VP16, ATG
27 Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation Unknown status NCT01217723 Phase 3
28 Hematopoietic Stem Cell Transplantation for Mucopolysaccharidosis Unknown status NCT01238328 Phase 2, Phase 3 Conditioning regimen;Graft-versus-host disease (GVHD) prophylaxis
29 Hematopoietic Stem Cell Transplantation for Malignant Infantile Osteopetrosis Unknown status NCT01087398 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Thymoglobulin, Fludarabine (Conditioning regimen);Cyclosporin, Methotrexate (GVHD prophylaxis)
30 Unrelated Double Umbilical Cord Blood Units Transplantation Unknown status NCT01015742 Phase 2, Phase 3 Stem cell Transplantation
31 The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host Disease Completed NCT00726375 Phase 3 Etanercept (Enbrel)
32 Study Comparing ABX-CBL (Monoclonal Antibody) Versus Atgam in Patients With Steroid Resistant Acute Graft Versus Host Disease Completed NCT00035880 Phase 2, Phase 3 ABX-CBL
33 Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease Completed NCT00929695 Phase 3 prednisone;methylprednisolone
34 Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease Completed NCT00366145 Phase 3
35 Methylprednisolone With or Without Daclizumab in Treating Patients With Acute Graft-Versus-Host Disease Completed NCT00053976 Phase 3 methylprednisolone;Placebo
36 Efficacy and Safety of Prochymal™ Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute GVHD Completed NCT00562497 Phase 3 Prochymal
37 Acute Graft-Versus-Host Disease (aGvHD) Prophylaxis With ATG-Fresenius in Matched Unrelated Donor-Stem Cell Transplantation (MUD-SCT) Completed NCT00655343 Phase 3 ATG-Fresenius S
38 Acute Graft-versus-Host Disease Treatment (BMT CTN 0802) Completed NCT01002742 Phase 3 Mycophenolate Mofetil;Placebo
39 Tacrolimus/Methotrexate Versus Cyclosporine/Methotrexate for Prophylaxis of Graft Versus Host Disease Completed NCT01788501 Phase 2, Phase 3 Tacrolimus;Cyclosporine;Methotrexate
40 Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00152139 Phase 3 Chemotherapy and antibodies
41 Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation Completed NCT00002456 Phase 3 cyclosporine;methotrexate
42 Thymoglobuline in Non-myeloablative Allogeneic Stem-cell Transplantation Completed NCT00130754 Phase 3 Thymoglobuline
43 Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) Completed NCT00406393 Phase 3 Tacrolimus;Methotrexate;Sirolimus
44 Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia Completed NCT00678275 Phase 3 ATG FRESENIUS (Anti-Lymphocyte-Globulin);ATG FRESENIUS (Anti-Lymphocyte-Globulin)
45 Budesonide for Prevention of Acute Gastrointestinal GVHD Following Allogenic Stem Cell Transplantation Completed NCT00180089 Phase 3 Budesonide
46 Randomized Trial Comparing Sirolimus and Tacrolimus Versus Cyclosporine and Methotrexate as Graft-versus-host Disease (GVHD) Prophylaxis After Allogeneic Stem Cell Transplantation Completed NCT00993343 Phase 3 Sirolimus/tacrolimus;cyclosporine/methotrexate
47 Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation Completed NCT00004255 Phase 2, Phase 3 cyclophosphamide;fludarabine phosphate;methylprednisolone;tacrolimus
48 Peripheral Blood (PB) Versus Bone Marrow (BM) in Allogeneic Stem Cell Transplantation Completed NCT01020175 Phase 3
49 Stem Cell Transplant for Inborn Errors of Metabolism Completed NCT00176904 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Antithymocyte Globulin
50 Nonmyeloablative Stem Cell Transplant in Elderly Completed NCT00382759 Phase 2, Phase 3

Search NIH Clinical Center for Acute Graft Versus Host Disease

Genetic Tests for Acute Graft Versus Host Disease

Anatomical Context for Acute Graft Versus Host Disease

MalaCards organs/tissues related to Acute Graft Versus Host Disease:

39
Bone, Bone Marrow, T Cells, Myeloid, Kidney, Nk Cells, Skin

Publications for Acute Graft Versus Host Disease

Articles related to Acute Graft Versus Host Disease:

(show top 50) (show all 732)
id Title Authors Year
1
Is It Time to Reconsider the Lipopolysaccharide Paradigm in Acute Graft-Versus-Host Disease? ( 28848554 )
2017
2
OSI-027 modulates acute graft-versus-host disease after liver transplantation in a rat model. ( 28590550 )
2017
3
A20 deletion in TA cells modulates acute graft-versus-host disease in mice. ( 28833031 )
2017
4
Protection of Mice from Acute Graft-versus-Host Disease Requires CD28 Co-stimulation on Donor CD4(+) Foxp3(+) Regulatory T Cells. ( 28690612 )
2017
5
Systemic Treatment with a miR-146a Mimic Suppresses Endotoxin Sensitivity and Partially Protects Mice from the Progression of Acute Graft-versus-Host Disease. ( 28853768 )
2017
6
Acute Graft-Versus-Host Disease Prognosis: Are Biomarkers Ready for Preemptive Clinical Trials? ( 28687636 )
2017
7
Correction: Endothelial microparticles delivering microRNA-155 into T lymphocytes are involved in the initiation of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. ( 28938702 )
2017
8
Acute graft-versus-host disease of the gut: considerations for the gastroenterologist. ( 28951581 )
2017
9
Mycophenolate mofetil is effective only for involved skin in the treatment for steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. ( 27766393 )
2017
10
The Effect of CCR5I932 on the Risk of Grade 3-4 Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. ( 28862353 )
2017
11
Predicting death in patients with acute graft-versus-host disease after reduced-intensity conditioning. ( 28863797 )
2017
12
Immune stimulation during chemotherapy increases incidence of acute graft versus host disease in acute myeloid leukemia: A study on behalf of SFGM-TC and ALFA. ( 28088653 )
2017
13
The association between acute graft-versus-host disease and antimicrobial peptide expression in the gastrointestinal tract after allogeneic stem cell transplantation. ( 28934349 )
2017
14
Mesenchymal Stromal Cells: What Is the Mechanism in Acute Graft-Versus-Host Disease? ( 28671556 )
2017
15
Evaluation of Serum Interleukin-21 and HLA-C1 Polymorphism in Pediatrician Hematopoietic Stem Cell Transplantation for Early Diagnosis of Acute Graft-Versus-Host Disease ( 28627158 )
2017
16
Bridging-to-transplant with Azacitidine for Myelodysplastic Syndrome and Acute Myeloid Leukemia, Reduces the Incidence of Acute Graft-versus-host Disease. ( 28670436 )
2017
17
Dynamics of M1 macrophages in oral mucosal lesions during the development of acute graft-versus-host disease in rats. ( 28862740 )
2017
18
EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis. ( 28733186 )
2017
19
Cutaneous acute graft-versus-host disease with isomorphic disposition over striae distensae in a 12-year-old girl. ( 27805255 )
2017
20
The Combination of Cyclosporine and Mycophenolate Mofetil is Less Effective than Cyclosporine and Methotrexate in the Prevention of Acute Graft-versus Host Disease after Stem-cell Transplantation from Unrelated Donors. ( 28052467 )
2017
21
Lessons Learned from Early Experiences with Vedolizumab for Steroid-Refractory Acute Graft- versus-Host Disease with Gastrointestinal Involvement. ( 28578009 )
2017
22
Fecal microbiota transplantation for acute graft-versus-host disease of the gut. ( 28592766 )
2017
23
Chitinase 3-like-1 deficient donor splenocytes accentuated the pathogenesis of acute graft-versus-host diseases through regulating T cell expansion and type I inflammation. ( 28324830 )
2017
24
Chitinase 3-Like-1-Deficient Splenocytes Deteriorated the Pathogenesis of Acute Graft-Versus-Host Disease via Regulating Differentiation of Tfh Cells. ( 28656528 )
2017
25
Peripheral blood Th9 cells reconstitution and its relationship with acute graft-versus-host disease after matched-sibling peripheral blood hematopoietic stem cell transplantation. ( 28861153 )
2017
26
Hsp90 inhibition ameliorates CD4(+) T cell-mediated acute Graft versus Host disease in mice. ( 27980780 )
2016
27
Circulating miRNA panel for prediction of acute graft-versus-host disease inA lymphoma patients undergoing matched unrelated hematopoietic stem cellA transplantation. ( 27013207 )
2016
28
High expression of heme oxygenase-1 in target organs may attenuate acute graft-versus-host disease through regulation of immune balance of TH17/Treg. ( 27168057 )
2016
29
Effect of Everolimus (RAD001) on Acute Graft-Versus-Host Disease in Mice. ( 27379528 )
2016
30
Conjunctival Acute Graft-versus-Host Disease in Adult Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Cohort Study. ( 27902756 )
2016
31
Vascular Alterations in a Murine Model of Acute Graft-Versus-Host Disease Are Associated With Decreased Serum Levels of Adiponectin and an Increased Activity and Vascular Expression of Indoleamine 2,3-Dioxygenase. ( 27931514 )
2016
32
Donor Cell Composition and Reactivity Predict Risk of Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. ( 27965986 )
2016
33
Successful salvage treatment of acute graft-versus-host disease after liver transplantation by withdrawal of immunosuppression: a case report. ( 26925149 )
2016
34
The role of danger signals and ectonucleotidases in acute graft-versus-host disease. ( 26902992 )
2016
35
Organsiderosis and hemophagocytosis during acute graft-versus-host disease. ( 27198715 )
2016
36
Novel approaches for preventing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. ( 27110922 )
2016
37
GRIM19 ameliorates acute graft-versus-host disease (GVHD) by modulating Th17 and Treg cell balance through down-regulation of STAT3 and NF-AT activation. ( 27391226 )
2016
38
Association of Cumulative Steroid Dose with Risk of Infection after Treatment for Severe Acute Graft-versus-Host Disease. ( 26968790 )
2016
39
Pathogenesis of acute graft-versus-host disease: from intestinal microbiota alterations to donor T cell activation. ( 27619472 )
2016
40
High-risk HLA alleles for severe acute graft-versus-host disease and mortality in unrelated donor bone marrow transplantation. ( 26768690 )
2016
41
Does defibrotide prophylaxis decrease the risk of acute graft versus host disease following allogeneic hematopoietic cell transplantation? ( 26922995 )
2016
42
Peritransplant Serum Albumin Decline Predicts Subsequent Severe Acute Graft-versus-Host Disease after Mucotoxic Myeloablative Conditioning. ( 26988741 )
2016
43
A Prospective Study of Alemtuzumab as a Second Line Agent for Steroid Refractory Acute Graft Versus Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplant. ( 27664325 )
2016
44
Endothelial microparticles carrying hedgehog-interacting protein induce continuous endothelial damage in the pathogenesis of acute graft-versus-host disease. ( 27009877 )
2016
45
Extracoporeal photopheresis treatment of acute graft-versus-host disease following allogeneic haematopoietic stem cell transplantation. ( 27408705 )
2016
46
Pretransplant I^2-Microglobulin Is Associated with the Risk of Acute Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplant. ( 27044906 )
2016
47
Extracellular vesicles released from human umbilical cord-derived mesenchymal stromal cells prevent life-threatening acute graft-versus-host disease in a mouse model of allogeneic hematopoietic stem cell transplantation. ( 27649744 )
2016
48
Late acute graft versus host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors. ( 27625357 )
2016
49
Narrow-Band Ultraviolet B Phototherapy Ameliorates Acute Graft-Versus-Host Disease of the Intestine by Expansion of Regulatory T Cells. ( 27031239 )
2016
50
Donor Killer Immunoglobulin-Like Receptor Haplotype B/X Induces Severe Acute Graft-Versus-Host Disease in the Presence of HLA Mismatch in T-Cell Replete Hematopoietic Cell Transplantation. ( 28042021 )
2016

Variations for Acute Graft Versus Host Disease

Expression for Acute Graft Versus Host Disease

Search GEO for disease gene expression data for Acute Graft Versus Host Disease.

Pathways for Acute Graft Versus Host Disease

Pathways related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.99 ARHGAP45 FASLG IFNG IL10 IL18 IL2
2
Show member pathways
13.79 FASLG IL10 IL18 IL2 IL2RA IL4
3
Show member pathways
13.65 FASLG IFNG IL10 IL18 IL2 IL2RA
4
Show member pathways
13.48 IFNG IL10 IL18 IL2 IL2RA IL4
5
Show member pathways
13.42 FASLG IL10 IL18 IL2 IL2RA IL4
6
Show member pathways
13.33 FASLG IFNG IL10 IL18 IL2 IL2RA
7
Show member pathways
13.31 FASLG IL10 IL18 IL2 IL2RA IL4
8
Show member pathways
12.88 FASLG GZMB IFNG IL10 IL2 IL2RA
9
Show member pathways
12.87 FASLG IFNG IL10 IL2 TNF
10
Show member pathways
12.83 FASLG IFNG IL18 IL2 IL2RA IL4
11
Show member pathways
12.72 IL2 IL2RA IL4 TNF
12
Show member pathways
12.68 IFNG IL10 IL18 IL2 IL2RA IL4
13 12.64 FASLG IL2 IL2RA IL4 TNF
14
Show member pathways
12.61 IFNG IL10 IL18 IL2 TNF
15
Show member pathways
12.58 FASLG GZMB IFNG IL2 IL4 TNF
16
Show member pathways
12.54 IFNG IL10 IL18 IL2 IL2RA IL4
17
Show member pathways
12.48 IFNG IL10 IL2 IL4 TNF
18 12.41 FASLG GZMB IFNG IL10 IL2 IL2RA
19 12.3 IFNG IL10 IL18 NOD2 TNF
20
Show member pathways
12.28 IFNG IL10 IL2 IL2RA IL4
21
Show member pathways
12.27 IFNG IL10 IL4 TNF
22
Show member pathways
12.23 IFNG IL10 IL18 IL2 IL4 TNF
23
Show member pathways
12.2 FASLG IFNG IL4 TNF
24 12.07 FASLG IL10 IL18 IL4 TNF
25 12.06 IFNG IL2 IL4 TNF
26 12.06 IFNG IL10 IL2 IL2RA IL4 TNF
27
Show member pathways
12.03 IFNG IL10 IL18 IL2 TNF
28
Show member pathways
12.02 IFNG IL2 IL2RA
29 11.93 IFNG IL10 IL2 IL2RA
30
Show member pathways
11.92 FASLG GZMB IFNG IL18 IL2 IL2RA
31
Show member pathways
11.9 GZMB IFNG IL4
32 11.88 IL2RA IL4 TNF
33 11.87 IFNG IL10 TNF
34 11.85 IFNG IL10 IL2 TNF
35 11.84 IFNG IL18 TNF
36
Show member pathways
11.81 FASLG TNF TNFRSF4
37 11.8 IFNG IL2 IL4
38 11.8 IL10 IL2RA IL4 TNF TNFRSF4
39
Show member pathways
11.79 FASLG IL2 IL2RA IL4
40
Show member pathways
11.79 FASLG IFNG IL2 IL2RA IL4 TNF
41
Show member pathways
11.68 IFNG IL2 TNF
42 11.65 FASLG IFNG IL2 TNF
43 11.62 IL10 IL18 IL4 TNF
44 11.62 IFNG IL10 IL18 TNF
45 11.55 IFNG IL2 TNF
46 11.55 IFNG IL18 TNF
47 11.52 FASLG IFNG TNF
48 11.52 IFNG IL10 IL2 IL2RA IL4 TNFRSF4
49
Show member pathways
11.49 FASLG GZMB IFNG IL2 IL2RA TNF
50 11.46 GZMB IFNG IL10 IL18 IL2 IL2RA

GO Terms for Acute Graft Versus Host Disease

Cellular components related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.8 FASLG IFNG IL10 IL18 IL2 IL4
2 extracellular region GO:0005576 9.56 ARHGAP45 FASLG IFNG IL10 IL18 IL2
3 cell surface GO:0009986 9.55 FASLG IL2RA NOD2 TNF TNFRSF4
4 external side of plasma membrane GO:0009897 9.02 FASLG IFNG IL2RA IL4 TNF

Biological processes related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
id Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.98 FASLG IL10 IL18 IL2
2 MAPK cascade GO:0000165 9.97 IL18 IL2 IL2RA TNF
3 inflammatory response GO:0006954 9.95 IL10 IL18 IL2RA TNF TNFRSF4
4 defense response to bacterium GO:0042742 9.93 IFNG IL10 NOD2 TNF
5 positive regulation of protein phosphorylation GO:0001934 9.89 IFNG IL2 IL4 TNF
6 cellular response to lipopolysaccharide GO:0071222 9.87 IFNG IL10 TNF
7 tumor necrosis factor-mediated signaling pathway GO:0033209 9.87 FASLG TNF TNFRSF4
8 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.86 IL10 IL4 TNF
9 negative regulation of inflammatory response GO:0050728 9.85 IL10 IL2 IL2RA
10 cellular response to organic cyclic compound GO:0071407 9.84 IL18 NOD2 TNF
11 apoptotic signaling pathway GO:0097190 9.83 FASLG TNF TNFRSF4
12 positive regulation of interferon-gamma production GO:0032729 9.79 IL18 IL2 TNF
13 extrinsic apoptotic signaling pathway GO:0097191 9.78 FASLG IFNG TNF
14 positive regulation of B cell proliferation GO:0030890 9.77 IL2 IL4 TNFRSF4
15 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.73 IFNG IL18 IL2 IL4
16 positive regulation of protein complex assembly GO:0031334 9.71 IFNG TNF
17 positive regulation of interleukin-10 production GO:0032733 9.71 IL4 NOD2
18 negative regulation of myoblast differentiation GO:0045662 9.71 IL18 TNF
19 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.71 IL10 TNF
20 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.71 NOD2 TNF
21 positive regulation of T cell proliferation GO:0042102 9.71 IFNG IL2 IL2RA IL4
22 natural killer cell activation GO:0030101 9.7 IL18 IL2
23 positive regulation of NF-kappaB import into nucleus GO:0042346 9.7 IL18 TNF
24 positive regulation of osteoclast differentiation GO:0045672 9.7 IFNG TNF
25 negative regulation of nitric oxide biosynthetic process GO:0045019 9.69 IL10 IL4
26 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.69 IFNG TNF
27 defense response to protozoan GO:0042832 9.69 IFNG IL10 IL4
28 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.68 IL10 TNF
29 positive regulation of immunoglobulin secretion GO:0051024 9.68 IL2 TNFRSF4
30 endothelial cell apoptotic process GO:0072577 9.67 IL10 TNF
31 positive regulation of T cell differentiation GO:0045582 9.67 IL2 IL2RA IL4
32 negative regulation of lymphocyte proliferation GO:0050672 9.65 IL2 IL2RA
33 necroptotic signaling pathway GO:0097527 9.65 FASLG TNF
34 negative regulation of cytokine secretion involved in immune response GO:0002740 9.65 IL10 TNF
35 negative regulation of growth of symbiont in host GO:0044130 9.65 IFNG IL10 TNF
36 positive regulation of tissue remodeling GO:0034105 9.64 IL18 IL2
37 negative regulation of T-helper 17 cell differentiation GO:2000320 9.63 IL2 IL4
38 positive regulation of interleukin-17 production GO:0032740 9.63 IL18 IL2 NOD2
39 regulation of isotype switching GO:0045191 9.62 IL10 IL4
40 positive regulation of mononuclear cell migration GO:0071677 9.62 IL4 TNF
41 receptor biosynthetic process GO:0032800 9.58 IL10 TNF
42 regulation of T cell homeostatic proliferation GO:0046013 9.58 IL2 IL2RA
43 inflammatory cell apoptotic process GO:0006925 9.57 FASLG IFNG
44 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.56 IFNG TNF
45 positive regulation of vitamin D biosynthetic process GO:0060557 9.54 IFNG TNF
46 positive regulation of isotype switching to IgG isotypes GO:0048304 9.54 IFNG IL2 IL4
47 positive regulation of chemokine biosynthetic process GO:0045080 9.5 IFNG IL4 TNF
48 positive regulation of MHC class II biosynthetic process GO:0045348 9.43 IFNG IL10 IL4
49 type 2 immune response GO:0042092 9.33 IL10 IL18 IL4
50 immune response GO:0006955 9.28 FASLG IFNG IL10 IL18 IL2 IL2RA

Molecular functions related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.17 FASLG IFNG IL10 IL18 IL2 IL4
2 growth factor activity GO:0008083 9.13 IL10 IL2 IL4

Sources for Acute Graft Versus Host Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....